BRUGIA, MARCO
 Distribuzione geografica
Continente #
NA - Nord America 1.574
EU - Europa 1.331
AS - Asia 364
AF - Africa 3
Totale 3.272
Nazione #
US - Stati Uniti d'America 1.568
RU - Federazione Russa 540
IT - Italia 245
PL - Polonia 218
IE - Irlanda 120
SG - Singapore 96
CN - Cina 94
HK - Hong Kong 89
SE - Svezia 78
JO - Giordania 41
AT - Austria 35
IN - India 31
DE - Germania 28
CH - Svizzera 17
GB - Regno Unito 13
FI - Finlandia 12
ES - Italia 8
VN - Vietnam 8
BE - Belgio 5
CA - Canada 5
TR - Turchia 4
UA - Ucraina 4
CI - Costa d'Avorio 3
NL - Olanda 3
FR - Francia 2
NO - Norvegia 2
MX - Messico 1
PK - Pakistan 1
PT - Portogallo 1
Totale 3.272
Città #
Santa Clara 588
Warsaw 214
Chandler 123
Dublin 120
Fairfield 100
Ashburn 93
Singapore 83
Florence 56
Hong Kong 56
Seattle 51
Cambridge 49
Houston 48
Woodbridge 45
Wilmington 36
Vienna 35
Beijing 33
Altamura 32
Lawrence 28
Ann Arbor 25
Shanghai 23
Moscow 21
Bremen 20
Princeton 20
New York 19
Bern 17
Mumbai 17
Boston 15
Boardman 14
Buffalo 14
Milan 13
Medford 12
Pune 12
Helsinki 9
Barcelona 8
Dong Ket 8
Los Angeles 8
Rome 8
Kent 7
Brescia 6
Brussels 5
Falls Church 5
Munich 5
Amandola 4
Cinisello Balsamo 4
London 4
Naples 4
San Diego 4
Yubileyny 4
Abidjan 3
Alba 3
Ancona 3
Hangzhou 3
Mykolayiv 3
San Marco Evangelista 3
Sesto Fiorentino 3
Shenzhen 3
Andover 2
Argelato 2
Brusaporto 2
Carmignano 2
Cernusco sul Naviglio 2
Dearborn 2
Forlì 2
Formia 2
Frankfurt Am Main 2
Guangzhou 2
Hillsboro 2
Istanbul 2
Laurel 2
Mileto 2
Newark 2
Norwalk 2
Oslo 2
Padova 2
Palermo 2
Parma 2
Phoenix 2
Pisa 2
Radomsko 2
San Giovanni Valdarno 2
Siena 2
Surrey 2
Taranto 2
Toronto 2
Turin 2
Varese 2
Vico Equense 2
Washington 2
West Jordan 2
Aprilia 1
Baotou 1
Central District 1
Hefei 1
Kilburn 1
Kunming 1
Lahore 1
Lappeenranta 1
Lisbon 1
Lucca 1
New Bedfont 1
Totale 2.226
Nome #
Emerging drugs in refractory colorectal cancer 275
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. 200
Analysis of Prognostic Factors for Resected Synchronous and Metachronous Liver Metastases from Colorectal Cancer. 143
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 141
A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 140
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect 132
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer 127
Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors. 125
D13Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 121
Physical exercise and eating habits in cancer survivors 121
Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study 119
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 109
Regorafenib also can cause osteonecrosis of the jaw 108
THE IMPACT OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY 106
Aflibercept plus folfiri as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience 97
Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 95
Association of systemic steroid treatment and outcome in patients treated with immune checkpoint inhibitors: A real-world analysis 93
Chasing the target: New phenomena of resistance to novel selective ret inhibitors in lung cancer. updated evidence and future perspectives 93
Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy 86
Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study 84
Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI 84
Results of the observational prospective RealFLOT study 83
Somatostatin analogs in pregnant patients with neuroendocrine tumor 79
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 76
In Regard to "Activity of EGFR TKIs in Caucasian Patients With NSCLC Harbouring Potentially Sensitive Uncommon EGFR Mutations" 75
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO 75
Current status and future perspectives in HER2 positive advanced gastric cancer 73
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 68
Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer 63
Long-term response of more than 9 years to regorafenib in a heavily pretreated patient with metastatic colorectal cancer 58
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 43
Pathological complete response achieved with FLOT chemotherapy in two patients with MSI-H esophagogastric junction and gastric adenocarcinoma 39
null 3
Totale 3.334
Categoria #
all - tutte 11.281
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.281


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020192 0 0 0 0 0 29 35 31 27 26 37 7
2020/2021287 21 25 2 36 43 30 22 15 27 33 20 13
2021/2022138 4 7 5 3 2 10 1 20 11 13 16 46
2022/2023651 32 110 18 60 45 121 70 55 80 9 20 31
2023/2024401 9 25 37 18 20 64 26 81 8 34 34 45
2024/20251.413 64 178 114 339 519 199 0 0 0 0 0 0
Totale 3.334